Univest
Univest
  • Markets

Albert David Share Price Target 2026 Analyst Forecast Bull and Bear Case

  • June 5, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Albert David Share Price Target 2026

The Albert David share price target 2026 is Rs 850, implying approximately 20 percent upside from the current market price of Rs 708.6 (NSE: ALBERTDAVD). Q4 FY26 results announced May 30, 2026 are the key near-term re-rating trigger, with Pharmaceutical Formulations and OTC Products tailwinds and RBI rate cuts supporting the path to Rs 850.

The Albert David share price target 2026 is Rs 850, based on analyst estimates and the FY27 earnings recovery thesis. Q4 FY26 results announced May 30, 2026 are the immediate trigger for re-rating Albert David (NSE: ALBERTDAVD). This article covers the complete Albert David share price target analysis including sector tailwinds, key risks, and the bull and bear case scenarios.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Albert David Company Overview
  • Why Is the Albert David Share Price Target Set at Rs 850 for 2026
    • FY27 Earnings Delivery and Revenue Acceleration
    • Structural Sector Tailwinds in Pharmaceutical Formulations and OTC Products
    • RBI Rate Cut Cycle and Lower Cost of Capital
    • Union Budget 2026-27 Policy Support
    • Improving FII Flows Post the April 2026 Tariff Shock
  • Albert David Share Price Targets: Short Term, 12 Month, and Long Term
    • Short Term Albert David Share Price Target: 3 to 6 Months
    • 12-Month Albert David Share Price Target 2026
    • Long Term Albert David Share Price Target: FY27 to FY28
  • Bull Case and Bear Case for the Albert David Share Price Target
    • Bull Case Albert David Share Price Target: Rs 1,050
    • Bear Case Albert David Share Price Target: Rs 565
  • Key Risks to the Albert David Share Price Target 2026
    • US Tariff and Global Macro Risk
    • Valuation and Earnings Miss Risk
    • Competitive Pressure in Pharmaceutical Formulations and OTC Products
    • FII Selling Pressure and Liquidity Risk
  • How to Invest in Albert David
  • FAQs on Albert David Share Price Target 2026
    • What is the Albert David share price target for 2026?
    • Is Albert David a good buy at the current price of Rs 708.6?
    • What is the 52 week high and low of Albert David?
    • What are the key risks to the Albert David share price target 2026?
    • What are the main catalysts for the Albert David share price target?
    • What is the Albert David share price target for 2027?

Albert David Company Overview

Albert David (NSE: ALBERTDAVD) is a Kolkata-based 80-year-legacy pharmaceutical company manufacturing ethical and OTC pharmaceuticals for hospital and retail networks across Eastern and South India. At CMP Rs 708.6 against a 52 week range of Rs 550 to Rs 980, the stock trades at a meaningful discount to its 52 week high. Market capitalisation stands at Rs 480 crore with a trailing PE of 15x.

Parameter Value
NSE Ticker ALBERTDAVD
Sector Pharmaceutical Formulations and OTC Products
CMP (May 30, 2026) Rs 708.6
52 Week High Rs 980
52 Week Low Rs 550
Market Cap Rs 480 crore
Trailing PE 15x
12-Month Analyst Target Rs 850
Bull Case Target Rs 1,050
Bear Case Target Rs 565

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.

  • Discover stocks investors are actively accumulating
  • High-conviction opportunities backed by research
  • Designed for the next phase of market growth

Unlock the latest Top Stock Picks now on Univest

See the Stocks →

Why Is the Albert David Share Price Target Set at Rs 850 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Albert David share price target 2026 of Rs 850 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results confirming the recovery trajectory are the most direct catalyst for re-rating from CMP Rs 708.6 toward the Albert David share price target of Rs 850.

Structural Sector Tailwinds in Pharmaceutical Formulations and OTC Products

The Pharmaceutical Formulations and OTC Products sector is expanding on the back of India’s strong domestic demand, PLI scheme support, and rising corporate investment. Albert David’s market position creates a structural growth runway supporting the Albert David share price target consensus of Rs 850 and the bull case of Rs 1,050.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle, which began in early 2026, reduces Albert David’s borrowing costs and stimulates demand across end markets. Lower interest costs improve EPS trajectory, directly supporting the Albert David share price target 2026 of Rs 850.

Union Budget 2026-27 Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Albert David’s Pharmaceutical Formulations and OTC Products operations, improving the probability of achieving the Albert David share price target of Rs 850.

Improving FII Flows Post the April 2026 Tariff Shock

As global macro conditions normalise post the April 2026 US tariff event, FII flows into quality Indian equities are recovering through FY27. At 15x PE, Albert David is positioned as a beneficiary of institutional reallocation supporting the path to Rs 850.

Albert David Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Albert David Share Price Target: 3 to 6 Months

The near-term Albert David share price target is anchored to support near the 52 week low of Rs 550. A confirmed Q4 FY26 earnings recovery and positive FY27 guidance are the triggers for an initial 10 to 15 percent re-rating toward Rs 850.

12-Month Albert David Share Price Target 2026

The 12-month Albert David share price target 2026 is Rs 850, implying approximately 20 percent upside from CMP Rs 708.6. This base case assumes in-line FY27 earnings delivery and partial FII flow normalisation. Track live on NSE ticker ALBERTDAVD.

Long Term Albert David Share Price Target: FY27 to FY28

For investors with a 2 to 3 year horizon, the long-term Albert David share price target is Rs 1,050 in the bull case, assuming full earnings delivery through FY27 to FY28 and sector re-rating in the Pharmaceutical Formulations and OTC Products space.

Bull Case and Bear Case for the Albert David Share Price Target

Bull Case Albert David Share Price Target: Rs 1,050

The bull case for the Albert David share price target of Rs 1,050 materialises when FY27 earnings beat analyst estimates, sector tailwinds accelerate, and FII flows return strongly to Indian equities. The stock re-rates toward higher peer multiples, making Rs 1,050 achievable within FY28.

Bear Case Albert David Share Price Target: Rs 565

The bear case sees the Albert David share price target testing Rs 565 if FY27 earnings disappoint and FII outflows persist. At Rs 565, the stock approaches the 52 week low support of Rs 550, requiring a full reassessment of the investment thesis.

Scenario Target Key Conditions
Bull Case Rs 1,050 FY27 earnings beat, sector re-rating, strong FII inflows
Base Case Rs 850 In-line FY27 delivery, partial FII recovery
Bear Case Rs 565 FY27 earnings miss, guidance cut, sustained FII outflows

Key Risks to the Albert David Share Price Target 2026

US Tariff and Global Macro Risk

The 26 percent US reciprocal tariff announced April 2, 2026 triggered FII outflows across Indian equities. Prolonged trade tension or a global demand slowdown remains the most prominent macro risk to the Albert David share price target 2026 of Rs 850.

Valuation and Earnings Miss Risk

Any FY27 earnings miss or guidance cut could trigger multiple compression, posing a direct risk to the Albert David share price target of Rs 850. Monitoring quarterly results closely is essential for investors in Albert David.

Competitive Pressure in Pharmaceutical Formulations and OTC Products

Intensifying competition in the Pharmaceutical Formulations and OTC Products sector could compress Albert David’s pricing power and market share over the medium term, which must be factored into any assessment of the Albert David share price target of Rs 850.

FII Selling Pressure and Liquidity Risk

Sustained FII outflows from Indian equities can delay re-rating toward the Albert David share price target of Rs 850 regardless of company-level operational improvement through FY27.

How to Invest in Albert David

Check the Univest Screener for live data

Begin by reviewing Albert David’s Q4 FY26 results, annual report, and FY27 guidance statements before forming a view on the Albert David share price target of Rs 850. Focus on revenue growth trajectory, margin trends, and management commentary on sector headwinds and opportunities.

Open a Demat and trading account with a SEBI registered stockbroker to buy Albert David (NSE: ALBERTDAVD) with full regulatory protection. Ensure KYC is complete and understand the Pharmaceutical Formulations and OTC Products sector dynamics before executing any position.

Plan your entry near the 52 week low support of Rs 550. A confirmed Q4 FY26 earnings uptick and positive FY27 guidance would strengthen the entry case for the Albert David share price target of Rs 850. Set a disciplined stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk, especially in smaller-cap Pharmaceutical Formulations and OTC Products companies where liquidity and volatility can amplify losses.

Always consult a SEBI registered financial advisor before investing based on any Albert David share price target estimate. A registered advisor personalises recommendations based on your risk profile and financial goals. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Albert David’s live price and get daily stock recommendations.

Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.

FAQs on Albert David Share Price Target 2026

What is the Albert David share price target for 2026?

Ans. The Albert David share price target 2026 is Rs 850, implying approximately 20 percent upside from CMP Rs 708.6. The bull case target is Rs 1,050 and the bear case target is Rs 565.

Is Albert David a good buy at the current price of Rs 708.6?

Ans. At Rs 708.6, Albert David offers potential upside to the share price target of Rs 850 if FY27 earnings recover as projected. Consult a SEBI registered financial advisor before making any investment decision.

What is the 52 week high and low of Albert David?

Ans. The 52 week high of Albert David is Rs 980 and the 52 week low is Rs 550. At CMP Rs 708.6, the stock offers upside potential toward the 12-month share price target of Rs 850.

What are the key risks to the Albert David share price target 2026?

Ans. Key risks to the Albert David share price target of Rs 850 include an FY27 earnings miss, US tariff-driven FII outflows, competitive pressure in Pharmaceutical Formulations and OTC Products, and broader market volatility.

What are the main catalysts for the Albert David share price target?

Ans. Primary catalysts include FY27 PAT recovery, structural tailwinds in Pharmaceutical Formulations and OTC Products, RBI rate cut support, Union Budget 2026-27 policy uplift, and FII flow normalisation into Indian equities through FY27.

What is the Albert David share price target for 2027?

Ans. The long-term Albert David share price target for FY27 to FY28 is Rs 1,050 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply